Techcyte awarded new AI patent, strengthening its AI training framework and accelerating development of digital diagnostics

Orem, Utah, 17 Dec. 2025 — Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced the issuance of a new patent covering a novel approach to training medical imaging algorithms using explicit labeling. This innovation eliminates the need for exhaustive “background” labeling and enables more efficient, scalable creation of high-quality training datasets.

In conventional machine-learning workflows for digital pathology, annotators are often required to exhaustively label all visible elements, such as tissue structures, organisms, cells, cellular features, and background areas, to ensure models learn correct distinctions. This process is labor-intensive, slow, and prone to misclassification. Techcyte’s patented method allows algorithms to be trained using only explicitly selected diagnostic and background elements, reducing the volume of manual annotation required while maintaining model accuracy and reliability.

“High-quality annotated data is the foundation of any clinical AI system, but creating it at scale has historically been one of the major bottlenecks in digital pathology,” said Rick Smith, co-founder of Techcyte. “This patent formalizes an approach that lets our teams label what truly matters, diagnostic foreground objects, and train models more efficiently with far less contributive data.”

The patented technique enhances the scalability of Techcyte’s unified digital pathology platform by enabling faster iteration cycles, expanding the diversity of training sets, and supporting rapid development across new diagnostic modalities. The ability to train high-performing models using fewer labeled examples is especially valuable in areas where expert annotation is limited or where rare findings are critical to clinical decision-making.

“This patent represents a key advancement in our diagnostic AI platform,” said Shane Swenson, CTO of Techcyte. “Our combined innovation in AI tools and techniques has led to an increasingly efficient model development pipeline, enabling us to rapidly grow our portfolio and deliver advanced digital diagnostics that can meaningfully improve accuracy, consistency, and turnaround times for the laboratories and clinicians we serve.”

The patent underscores Techcyte’s continued investment in foundational AI technologies that advance pathology practice and support its mission to unify and modernize workflows for human, veterinary, and environmental markets.